摘要
目的寻找一个早期预测骨髓增生异常综合征（ＭＤＳ）向急性髓系白血病（ＡＭＬ）转化的指标。方法对ＭＤＳ患者４５例，ＡＭＬ患者４０例，对照组５０例，利用放射免疫法（ＲＩＡ）检测其血清中的人降钙素（ｈＣＴ）、降钙素基因相关肽（ＣＧＲＰ）水平，并对ＭＤＳＲＡ组、ＲＡＥＢ组中部分患者进行随访，观察其临床转归及与ｈＣＴ、ＣＧＲＰ血清水平的关系。结果ＭＤＳ各型及ＡＭＬ初发组患者ｈＣＴ、ＣＧＲＰ血清水平均有升高，与对照组相比差异均有显著性（Ｐ＜０．０１），ＲＡＥＢ组高于ＲＡ组（Ｐ＜０．０５），在ＲＡ向ＲＡＥＢ、ＲＡＥＢ向ＡＭＬ转化过程中ｈＣＴ、ＣＧＲＰ均逐渐升高。结论ｈＣＴ。
Objective To find out indications for predicting MDS transforming into AML. Methods Serum levels of human calcitonin (hCT) and calcitonin gene related peptide (CGRP) were measured in 45 patients with myelodysplastic syndromes (MDS), 40 with acute myeloid leukemia (AML) and 50 controls by radioimmunoassay (RIA). Some patients in RA or RAEB stages were followed up to study changes in serum hCT and CGRP levels during clinical evolution. Results hCT and CGRP were of high level in the sera of patients with MDS and de novo AML, which were significantly different from those of the controls (P<0.01), and were higher in RAEB group than in RA group. hCT and CGRP levels increased gradually as RA was evolving into RAEB or RAEB was evolving into AML. Conclusion The serum levels of hCT and CGRP can be used as indices for the early prediction of MDS evolving into AML.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1999年第2期79-81,共3页
Chinese Journal of Hematology
关键词
骨髓增生异常
综合征
降钙素
CGRP
测定
Myelodysplastic syndromes Calcitonin Calcitonin gene related peptide
